These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1281 related items for PubMed ID: 25567908

  • 1. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA.
    Clin Cancer Res; 2015 Aug 15; 21(16):3631-9. PubMed ID: 25567908
    [Abstract] [Full Text] [Related]

  • 2. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM, Kim EY, Kim HR, Ali SM, Greenbowe JR, Shim HS, Chang H, Lim S, Paik S, Cho BC.
    Oncotarget; 2016 Apr 26; 7(17):24172-8. PubMed ID: 26992220
    [Abstract] [Full Text] [Related]

  • 3. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB, Ilouze M, Dudnik E, Dvir A, Soussan-Gutman L, Geva S, Peled N.
    J Thorac Oncol; 2017 Feb 26; 12(2):258-268. PubMed ID: 27865871
    [Abstract] [Full Text] [Related]

  • 4. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, Stephens PJ, Ross JS.
    Oncologist; 2016 Jun 26; 21(6):684-91. PubMed ID: 27151654
    [Abstract] [Full Text] [Related]

  • 5. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC, Lai GGY, Tan GS, Poon SY, Doble B, Lim TH, Aung ZW, Takano A, Tan WL, Ang MK, Tan BS, Devanand A, Too CW, Gogna A, Ong BH, Koh TPT, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Lim AST, Lim WT, Toh CK, Tan EH, Lim TKH, Tan DSW.
    Lung Cancer; 2020 Jan 26; 139():207-215. PubMed ID: 31835042
    [Abstract] [Full Text] [Related]

  • 6. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M.
    Oncologist; 2019 Nov 26; 24(11):e1070-e1081. PubMed ID: 30902917
    [Abstract] [Full Text] [Related]

  • 7. [THE IMPACT OF MOLECULAR PROFILING USING NEXT-GENERATION SEQUENCING IN ADVANCED LUNG CANCER].
    Belilovski Rozenblum A, Ilouze M, Dudnik E, Soussan-Gutman L, Dvir A, Peled N.
    Harefuah; 2017 Nov 26; 156(11):686-691. PubMed ID: 29198084
    [Abstract] [Full Text] [Related]

  • 8. Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing.
    El Zaitouni S, Laraqui A, Ghaouti M, Benzekri A, Kettani F, Boustany Y, Benmokhtar S, Lamrani Alaoui H, El Annaz H, Abi R, Tagajdid MR, El Kochri S, El Mchichi B, Bouaiti EA, Lahlou IA, El Hassani RA, Ennibi K.
    Technol Cancer Res Treat; 2024 Nov 26; 23():15330338241288907. PubMed ID: 39363851
    [Abstract] [Full Text] [Related]

  • 9. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
    Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L.
    Ann Oncol; 2019 Feb 01; 30(2):290-296. PubMed ID: 30535340
    [Abstract] [Full Text] [Related]

  • 10. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J, Liu Y.
    Pathol Res Pract; 2020 Feb 01; 216(2):152797. PubMed ID: 31926773
    [Abstract] [Full Text] [Related]

  • 11. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
    Clin Lung Cancer; 2020 May 01; 21(3):e182-e190. PubMed ID: 31839532
    [Abstract] [Full Text] [Related]

  • 12. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
    Velizheva NP, Rechsteiner MP, Valtcheva N, Freiberger SN, Wong CE, Vrugt B, Zhong Q, Wagner U, Moch H, Hillinger S, Schmitt-Opitz I, Soltermann A, Wild PJ, Tischler V.
    Pathol Res Pract; 2018 Apr 01; 214(4):572-578. PubMed ID: 29580750
    [Abstract] [Full Text] [Related]

  • 13. Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
    Chen L, Chen M, Lin J, Chen X, Yu X, Chen Z, Jin L.
    Int J Clin Exp Pathol; 2020 Apr 01; 13(3):525-535. PubMed ID: 32269691
    [Abstract] [Full Text] [Related]

  • 14. Next-Generation Sequencing Approach to Non-Small Cell Lung Carcinoma Yields More Actionable Alterations.
    Mehrad M, Roy S, Bittar HT, Dacic S.
    Arch Pathol Lab Med; 2018 Mar 01; 142(3):353-357. PubMed ID: 29219616
    [Abstract] [Full Text] [Related]

  • 15. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG, Janse S, Owen DH, Kiourtsis S, Bertino EM, He K, Carbone DP, Otterson GA.
    Clin Lung Cancer; 2021 Jul 01; 22(4):e519-e527. PubMed ID: 33414052
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
    Vigneswaran J, Tan YH, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R.
    Oncotarget; 2016 Apr 05; 7(14):18876-86. PubMed ID: 26934441
    [Abstract] [Full Text] [Related]

  • 18. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
    Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ, LCMC2 investigators.
    Clin Cancer Res; 2018 Mar 01; 24(5):1038-1047. PubMed ID: 29217530
    [Abstract] [Full Text] [Related]

  • 19. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Mack PC, Klein MI, Ayers KL, Zhou X, Guin S, Fink M, Rossi M, Ai-Kateb H, O'Connell T, Hantash FM, Oh WK, Newman S, Schadt EE, Chen R, Hirsch FR.
    Oncologist; 2022 Jun 08; 27(6):476-486. PubMed ID: 35298662
    [Abstract] [Full Text] [Related]

  • 20. RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib.
    Mukhopadhyay S, Pennell NA, Ali SM, Ross JS, Ma PC, Velcheti V.
    J Thorac Oncol; 2014 Nov 08; 9(11):1714-9. PubMed ID: 25436805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.